Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT4406F in Minimal Change Disease and Focal Segmental Glomerulosclerosis
NCT07499700Phase 3Recruiting
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Oct 2025
- Primary completion
- Oct 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of BAT4406F in minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), sponsored by Bio-Thera Solutions, Ltd.. Started Oct 2025; status: recruiting.
02
Drugs
BAT4406F
03
Conditions
minimal change disease (MCD)focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT07499700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07499700.